Background:
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: November 2018: The following drug classes/subclass and newly approved agents will be reviewed:

MIGRAINE AGENTS - CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONIST: Ajovy; Emgality

ACNE AGENTS - TOPICAL ACNE AND ROSACEA: Altreno; Plixda

ANTIBIOTICS - AMINOGLYCOSIDES: Arikayce

ONCOLOGICAL AGENTS - CLL: Copiktra

ANTIRETROVIRALS - COMBINATIONS: Delstrigo

ANTICONVULSANTS-ANTIMANIA AGENTS - N/A: Epidiolex

ANTIHEMOPHILIC FACTORS - N/A: Jivi

ANTIBIOTICS - TETRACYCLINES: Minolira

HEMATOLOGICAL AGENTS - WHITE BLOOD CELLS STIMULANTS: Nivestim

ANTIRETROVIRALS - NUCLEOSIDE / NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR: Pifeltro

ONCOLOGICAL AGENTS - N/A: Vizimpro

ANTIBIOTICS - QUINOLONES: Xepi

PAIN AGENTS - LOCAL: ZTLido

RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.
There is no pre-proposal teleconference. Rather, questions shall be submitted via e-mail to the Request for Quote (RFQ) Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required.

POCs: Part 2.3 of the RFQ.
For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD

Bid Protests Not Available